<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
        {font-family:Helvetica;
        panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
        {font-family:Wingdings;
        panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:Tahoma;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
        {font-family:Georgia;
        panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
        {font-family:Verdana;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:purple;
        text-decoration:underline;}
p
        {mso-style-priority:99;
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
        {mso-style-priority:99;
        mso-style-link:"Balloon Text Char";
        margin:0cm;
        margin-bottom:.0001pt;
        font-size:8.0pt;
        font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
        {mso-style-name:"Balloon Text Char";
        mso-style-priority:99;
        mso-style-link:"Balloon Text";
        font-family:"Tahoma","sans-serif";}
span.EmailStyle20
        {mso-style-type:personal;
        font-family:"Calibri","sans-serif";
        color:windowtext;}
span.EmailStyle21
        {mso-style-type:personal;
        font-family:"Calibri","sans-serif";
        color:#1F497D;}
span.EmailStyle22
        {mso-style-type:personal-reply;
        font-family:"Calibri","sans-serif";
        color:#1F497D;}
.MsoChpDefault
        {mso-style-type:export-only;
        font-size:10.0pt;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
        {page:WordSection1;}
/* List Definitions */
@list l0
        {mso-list-id:1242445210;
        mso-list-template-ids:585662890;}
@list l0:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:36.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Symbol;}
@list l0:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:72.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:"Courier New";
        mso-bidi-font-family:"Times New Roman";}
@list l0:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:108.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:144.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level5
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:180.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:216.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:252.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level8
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:288.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l0:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:324.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1
        {mso-list-id:1622689488;
        mso-list-template-ids:-1655134788;}
@list l1:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:36.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Symbol;}
@list l1:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:72.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:"Courier New";
        mso-bidi-font-family:"Times New Roman";}
@list l1:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:108.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:144.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level5
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:180.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:216.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:252.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level8
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:288.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l1:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:324.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2
        {mso-list-id:1789275365;
        mso-list-template-ids:870119742;}
@list l2:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:36.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Symbol;}
@list l2:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:72.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:"Courier New";
        mso-bidi-font-family:"Times New Roman";}
@list l2:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:108.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:144.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level5
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:180.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:216.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:252.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level8
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:288.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l2:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:324.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3
        {mso-list-id:1890728817;
        mso-list-template-ids:1240384050;}
@list l3:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:36.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Symbol;}
@list l3:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:72.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:"Courier New";
        mso-bidi-font-family:"Times New Roman";}
@list l3:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:108.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:144.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level5
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:180.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:216.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:252.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level8
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:288.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l3:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:324.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4
        {mso-list-id:2069113373;
        mso-list-template-ids:-1407672272;}
@list l4:level1
        {mso-level-number-format:bullet;
        mso-level-text:\F0B7;
        mso-level-tab-stop:36.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Symbol;}
@list l4:level2
        {mso-level-number-format:bullet;
        mso-level-text:o;
        mso-level-tab-stop:72.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:"Courier New";
        mso-bidi-font-family:"Times New Roman";}
@list l4:level3
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:108.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level4
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:144.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level5
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:180.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level6
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:216.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level7
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:252.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level8
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:288.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
@list l4:level9
        {mso-level-number-format:bullet;
        mso-level-text:\F0A7;
        mso-level-tab-stop:324.0pt;
        mso-level-number-position:left;
        text-indent:-18.0pt;
        mso-ansi-font-size:10.0pt;
        font-family:Wingdings;}
ol
        {margin-bottom:0cm;}
ul
        {margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1030" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Below is the Janssen “Connect” newsletter.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Janssen Canada CONNECT [JOICA] [mailto:RA-JOICA-JanCanaCONN@ITS.JNJ.com] <br><b>Sent:</b> January 5, 2015 12:11 PM<br><b>To:</b> Janssen Canada CONNECT [JOICA]<br><b>Subject:</b> CONNECT - Publication 10<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal><img width=600 height=140 id="Picture_x0020_4" src="cid:image001.png@01D028DF.E9926D50" alt="Connect newsletter banner"><span style='font-size:12.0pt'><o:p></o:p></span></p></td></tr><tr><td style='padding:15.0pt 0cm 15.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:18.0pt;font-family:"Helvetica","sans-serif";color:#444444'>Engaging Canadians on Health Policy Matters <o:p></o:p></span></p></td></tr><tr><td style='border-top:solid #DDDDDD 1.0pt;border-left:none;border-bottom:solid #DDDDDD 1.0pt;border-right:none;padding:7.5pt 0cm 7.5pt 0cm'><p class=MsoNormal align=center style='text-align:center'>December 2014 <span style='font-size:12.0pt'><o:p></o:p></span></p></td></tr><tr><td style='padding:22.5pt 0cm 22.5pt 0cm'><p class=MsoNormal align=center style='text-align:center'><img width=280 height=279 id="Picture_x0020_3" src="cid:image002.gif@01D028DF.E9926D50" alt="Connect speech bubble"><span style='font-size:12.0pt'><o:p></o:p></span></p></td></tr><tr><td style='padding:7.5pt 0cm 7.5pt 0cm'><p class=MsoNormal><span style='font-size:24.0pt;color:#009FD0'>Welcome to the December 2014 edition of CONNECT! <o:p></o:p></span></p></td></tr><tr><td style='padding:0cm 0cm 11.25pt 0cm'><p>In today's CONNECT we're looking at:<o:p></o:p></p><ul type=disc><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l1 level1 lfo1'>Recent developments at CADTH<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l1 level1 lfo1'>Janssen’s recent roundtable on patient involvement in the life-cycle of new medicines<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l1 level1 lfo1'>Patient navigators in Canada<span style='font-size:12.0pt'><o:p></o:p></span></li></ul></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellpadding=0 width=600 style='width:450.0pt;background:#714796'><tr><td style='padding:0cm 7.5pt 7.5pt 7.5pt'><p><span style='font-family:"Helvetica","sans-serif";color:#F8F8F8'>As this is our last edition in 2014, the Janssen Community Relations team would like to wish you all a joyous holiday season and a very Happy New Year!<o:p></o:p></span></p></td></tr></table></div></td></tr><tr><td style='border:none;border-bottom:solid #CCCCCC 1.0pt;padding:22.5pt 0cm 3.75pt 0cm'><p class=MsoNormal style='margin-bottom:11.25pt;line-height:22.5pt'><span style='font-size:21.0pt;color:#009FD0'>Recent Developments at CADTH <o:p></o:p></span></p></td></tr><tr><td style='padding:11.25pt 0cm 0cm 0cm'><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter" />
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0" />
<v:f eqn="sum @0 1 0" />
<v:f eqn="sum 0 0 @1" />
<v:f eqn="prod @2 1 2" />
<v:f eqn="prod @3 21600 pixelWidth" />
<v:f eqn="prod @3 21600 pixelHeight" />
<v:f eqn="sum @0 0 1" />
<v:f eqn="prod @6 1 2" />
<v:f eqn="prod @7 21600 pixelWidth" />
<v:f eqn="sum @8 21600 0" />
<v:f eqn="prod @7 21600 pixelHeight" />
<v:f eqn="sum @10 21600 0" />
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" />
<o:lock v:ext="edit" aspectratio="t" />
</v:shapetype><v:shape id="Picture_x0020_8" o:spid="_x0000_s1026" type="#_x0000_t75" alt="Doctor reviewing drugs data for review." style='position:absolute;margin-left:483.15pt;margin-top:0;width:212.25pt;height:141.75pt;z-index:251656192;visibility:visible;mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:right;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line;mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;mso-height-relative:page' o:allowoverlap="f">
<v:imagedata src="cid:image003.jpg@01D028DF.E9926D50" o:title="Doctor reviewing drugs data for review" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=283 height=189 src="cid:image003.jpg@01D028DF.E9926D50" align=right alt="Doctor reviewing drugs data for review." v:shapes="Picture_x0020_8"><![endif]>We’d like to update you on some recent developments at the <a href="http://www.cadth.ca/en/products/cdr/patient-group-input/update-for-patient-groups"><span style='color:#009FD0'>Canadian Agency for Drugs and Technologies in Health (CADTH):</span></a><o:p></o:p></p><ul type=disc><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l4 level1 lfo2'>The agency has produced videos on patient input, <a href="https://www.youtube.com/playlist?list=PL45wcLqNa3c6sYRD7XLM9akLF3y6dbz3W"><span style='color:#009FD0'>which can be viewed on YouTube.</span></a><o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l4 level1 lfo2'>The agency has provided tips on patient submissions, encouraging patient groups to be specific about the advantages and limitations of current treatments.<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l4 level1 lfo2'>Elaine MacPhail, who played an important role in establishing CADTH's process for patient group input, has announced her retirement.<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l4 level1 lfo2'>Ken Bond, who recently joined CADTH as Director of Strategic Initiatives, will be responsible for patient engagement at the agency.<span style='font-size:12.0pt'><o:p></o:p></span></li></ul></td></tr><tr><td style='border:none;border-bottom:solid #CCCCCC 1.0pt;padding:22.5pt 0cm 3.75pt 0cm'><p class=MsoNormal style='margin-bottom:11.25pt;line-height:22.5pt'><span style='font-size:21.0pt;color:#009FD0'>Janssen Roundtable on Patient Involvement in the Life-Cycle of New Medicines <o:p></o:p></span></p></td></tr><tr><td style='padding:11.25pt 0cm 0cm 0cm'><p><!--[if gte vml 1]><v:shape id="Picture_x0020_7" o:spid="_x0000_s1027" type="#_x0000_t75" alt="Doctor reviewing drugs data for review." style='position:absolute;margin-left:483.15pt;margin-top:0;width:212.25pt;height:141.75pt;z-index:251657216;visibility:visible;mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:right;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line;mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;mso-height-relative:page' o:allowoverlap="f">
<v:imagedata src="cid:image004.jpg@01D028DF.E9926D50" o:title="Doctor reviewing drugs data for review" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=283 height=189 src="cid:image004.jpg@01D028DF.E9926D50" align=right alt="Doctor reviewing drugs data for review." v:shapes="Picture_x0020_7"><![endif]>In October 2014, Janssen engaged with national patient group representatives to discuss patient involvement throughout the lifecycle of medicines. This was an opportunity for our colleagues with global responsibilities for Janssen and patient group representatives to exchange on best practices, challenges and potential solutions on positioning patients at the centre of healthcare decisions.<o:p></o:p></p><p>A number of themes emerged from these discussions, including:<o:p></o:p></p><ul type=disc><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>patients should be engaged at every step of the lifecycle of medicines, including early on in the drug development process, the regulatory process, the health technology assessment (HTA) process, the funding decisions and real world evidence studies <o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>what value means from the perspective of patients needs to be captured, as value often means something very different from the perspective of payers or healthcare providers <o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>patients need to be involved in determining what is important to them and how this should be measured <o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>the HTA process should be broadened to factor in criteria beyond drug costs <o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>more transparency is needed on how patient input is factored into the HTA process<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>more weight should be put on patient input in the context of reimbursement recommendations <o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l3 level1 lfo3'>patient groups face many challenges when developing submissions for HTA processes, including patient literacy issues and difficulties locating patients due to privacy laws<o:p></o:p></li></ul><p>A more detailed summary of these discussions is available upon request. As well, if you are interested in sharing your perspectives on this topic, including any best practices, Janssen would love to hear from you! You can contact us at: <a href="mailto:RA-JOICA-JanCanaCONN@ITS.JNJ.com">RA-JOICA-JanCanaCONN@ITS.JNJ.com</a>.<o:p></o:p></p></td></tr><tr><td style='border:none;border-bottom:solid #CCCCCC 1.0pt;padding:22.5pt 0cm 3.75pt 0cm'><p class=MsoNormal style='margin-bottom:11.25pt;line-height:22.5pt'><span style='font-size:21.0pt;color:#009FD0'>Patient Navigators <o:p></o:p></span></p></td></tr><tr><td style='padding:11.25pt 0cm 0cm 0cm'><p>In the past decade, patient navigators have become more common in the healthcare environment in Canada. The role of patient navigators is typically to help patients understand the healthcare system and access the care they need. While their responsibilities vary depending on the navigation program, they can include:<o:p></o:p></p><ul type=disc><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>scheduling appointments<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>arranging transportation<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>accompanying patients<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>connecting patients to the right doctors or resources<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>health education<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>counselling<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo4'>helping patients access available therapies<o:p></o:p></li></ul><p>In Canada, one of the first navigation programs was established in 2001 in Nova Scotia in its cancer care system. Given its success, many other provinces followed suit and patient navigation programs can now be found in nearly all provinces. These programs typically focus on people living with cancer and navigators are often nurses by profession. Some jurisdictions, such as Nova Scotia and Quebec, require that navigators meet certain requirements before they can take on this role, officially.<o:p></o:p></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_6" o:spid="_x0000_s1028" type="#_x0000_t75" alt="Doctor reviewing drugs data for review." style='position:absolute;margin-left:0;margin-top:0;width:212.25pt;height:141.75pt;z-index:251658240;visibility:visible;mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line;mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;mso-height-relative:page' o:allowoverlap="f">
<v:imagedata src="cid:image005.jpg@01D028DF.E9926D50" o:title="Doctor reviewing drugs data for review" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=283 height=189 src="cid:image005.jpg@01D028DF.E9926D50" align=left alt="Doctor reviewing drugs data for review." v:shapes="Picture_x0020_6"><![endif]>Navigation programs are now being used in areas other than cancer, such as chronic disease management. These navigators are sometimes called “health system navigators”, as they often help address system-related barriers, such as ensuring better case management and effective use of resources as well as providing patient education.<o:p></o:p></p><p>Some navigation programs have evolved towards adopting more culturally sensitive approaches. For instance, many programs have been introduced across Canada to serve Aboriginal communities and a program in Toronto was created specifically for the Chinese Canadian population. Generally, these navigators are “peers”, and can include people from the same culture and community and even cancer survivors. These navigators are able to address language and cultural needs or gaps.<o:p></o:p></p><p>Some navigators are specifically focussed on assisting patients with drug coverage. For instance, the Oncology Drug Access Navigators of Ontario (ODANO) is a provincial organization that helps maximize the appropriate funding for cancer patients. These navigators help facilitate drug coverage by:<o:p></o:p></p><ul type=disc><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l2 level1 lfo5'>accessing government funding through programs such as Ontario’s Exceptional Access Program<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l2 level1 lfo5'>accessing compassionate use programs<o:p></o:p></li><li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l2 level1 lfo5'>finding other reimbursement programs for unfunded drugs<o:p></o:p></li></ul><p>Recently, the Canadian Cancer Action Network (CCAN) hired a Patient Health Technology Assessment Navigator to assist patient advocacy groups in navigating the pan-Canadian Oncology Drug Review (pCODR) process. This ongoing pilot project, which is a first in Canada, is meant to provide patients groups with the required support to optimize their patient input submissions to pCODR, as well as develop, identify and support opportunities for patient and caregiver involvement in the pCODR process.<o:p></o:p></p><p>Finally, family members and caregivers also play an important navigation role by providing emotional support, accompanying the patient through his or her journey and advocating for patients when needed. They can also help optimize the role of professional patient navigators by providing them with information on patient preferences and pushing for better and more coordinated services when necessary.<o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellpadding=0 width=600 style='width:450.0pt;background:#714796'><tr><td width="48%" style='width:48.0%;padding:7.5pt 7.5pt 7.5pt 7.5pt'><p><!--[if gte vml 1]><v:shape id="Picture_x0020_5" o:spid="_x0000_s1029" type="#_x0000_t75" alt="Engaging Canadians logo" style='position:absolute;margin-left:0;margin-top:0;width:56.25pt;height:57.75pt;z-index:251659264;visibility:visible;mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line;mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;mso-height-relative:page' o:allowoverlap="f">
<v:imagedata src="cid:image006.gif@01D028DF.E9926D50" o:title="Engaging Canadians logo" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><img width=75 height=77 src="cid:image006.gif@01D028DF.E9926D50" align=left alt="Engaging Canadians logo" v:shapes="Picture_x0020_5"><![endif]><span style='font-size:13.5pt;font-family:"Georgia","serif";color:#F8F8F8'>Engaging Canadians on Health Policy Matters<o:p></o:p></span></p></td><td width="45%" style='width:45.0%;padding:7.5pt 7.5pt 7.5pt 7.5pt'><p class=MsoNormal align=right style='text-align:right'><span style='font-size:10.0pt;color:#F8F8F8'>If you wish to subscribe to this newsletter, <a href="mailto:janssencanadaconnect%40its.jnj.com?subject=Subscribe%20to%20Connect%20newsletter"><span style='color:#F8F8F8'>CLICK HERE!</span></a> <o:p></o:p></span></p></td></tr></table></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=170 height=37 id="Picture_x0020_2" src="cid:image007.gif@01D028DF.E9926D50" alt="Janssen logo"><span style='font-size:12.0pt'><o:p></o:p></span></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:8.5pt'>If you wish to unsubscribe to this newsletter, <a href="mailto:janssencanadaconnect%40its.jnj.com?subject=Unsubscribe%20to%20Connect%20newsletter">CLICK HERE.</a> <o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>With thanks,<o:p></o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><b><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>Wendy Gerhart</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'> <br>Community Relations <br></span><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif"'>Janssen <br><span style='color:black'>Office: 705-322-9757</span> / <span style='color:black'>Cell: 705-715-2162</span> <br><span style='color:black'>Email: <a href="mailto:wgerhart@its.jnj.com">wgerhart@its.jnj.com</a></span> <o:p></o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif"'><img border=0 width=299 height=94 id="Picture_x0020_1" src="cid:image008.png@01D028DF.E9926D50" alt="cid:image001.png@01CB97B3.19C21100"></span><span lang=EN-US><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p></div></body></html>